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Abstract
Background: Diagnosing pigmented skin lesions in general practice is challenging. SIAscopy has been shown to
increase diagnostic accuracy for melanoma in referred populations. We aimed to develop and validate a scoring
system for SIAscopic diagnosis of pigmented lesions in primary care.
Methods: This study was conducted in two consecutive settings in the UK and Australia, and occurred in three
stages: 1) Development of the primary care scoring algorithm (PCSA) on a sub-set of lesions from the UK sample;
2) Validation of the PCSA on a different sub-set of lesions from the same UK sample; 3) Validation of the PCSA on
a new set of lesions from an Australian primary care population. Patients presenting with a pigmented lesion were
recruited from 6 general practices in the UK and 2 primary care skin cancer clinics in Australia. The following data
were obtained for each lesion: clinical history; SIAscan; digital photograph; and digital dermoscopy. SIAscans were
interpreted by an expert and validated against histopathology where possible, or expert clinical review of all
available data for each lesion.
Results: A total of 858 patients with 1,211 lesions were recruited. Most lesions were benign naevi (64.8%) or
seborrhoeic keratoses (22.1%); 1.2% were melanoma. The original SIAscopic diagnostic algorithm did not perform
well because of the higher prevalence of seborrhoeic keratoses and haemangiomas seen in primary care. A primary
care scoring algorithm (PCSA) was developed to account for this. In the UK sample the PCSA had the following
characteristics for the diagnosis of ‘suspicious’: sensitivity 0.50 (0.18-0.81); specificity 0.84 (0.78-0.88); PPV 0.09 (0.03-
0.22); NPV 0.98 (0.95-0.99). In the Australian sample the PCSA had the following characteristics for the diagnosis of
‘suspicious’: sensitivity 0.44 (0.32-0.58); specificity 0.95 (0.93-0.97); PPV 0.52 (0.38-0.66); NPV 0.95 (0.92-0.96). In an
analysis of lesions for which histological diagnosis was available (n = 111), the PCSA had a significantly greater
Area Under the Curve than the 7-point checklist for the diagnosis of melanoma (0.83; 95% CI 0.71-0.95 versus 0.61;
95% CI 0.44-0.78; p = 0.02 for difference).
Conclusions: The PCSA could have a useful role in improving primary care management of pigmented skin
lesions. Further work is needed to develop and validate the PCSA in other primary care populations and to
evaluate the cost-effectiveness of GP management of pigmented lesions using SIAscopy.
Background
Pigmented skin lesions are a common presenting problem
in general practice and, while the majority are
benign naevi or non-melanocytic lesions (seborrhoeic ker-
atoses, haemangiomas), a small minority are malignant
melanomas. Melanoma is a serious skin cancer, responsi-
ble for 2% of all cancers and 1% of all cancer deaths in the
UK, with about 8,000 new cases and 1,800 deaths a year
[1]. Worldwide, the incidence of melanoma is increasing
faster than any other solid cancer with an approximate
doubling of rates every 10-20 years in countries with Cau-
casian populations [2,3].
Pigmented lesions and melanoma pose particular diag-
nostic and management challenges for general practi-
tioners (GPs) [4]. GPs are less able than dermatologists
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lesions [5,6], probably because an individual GP will
encounter melanoma infrequently [7]. British data fol-
lowing the establishment of urgent referral pathways for
all suspected skin cancers [8] showed that only 12% of
referred lesions were diagnosed as skin cancer and only
42% of skin cancers were referred via this route [9].
There have been conflicting findings about the perfor-
mance of GPs who have been trained in melanoma diag-
nosis either face-to-face [10] or via the internet [11].
In a primary care setting the ability to distinguish
benign from suspicious lesions is as important as a clini-
cal diagnosis of melanoma in making the decision either
to reassure or to refer urgently for dermatological
review. Studies of diagnostic accuracy and decision aids
for use in primary care need to reflect the diagnostic
distinction between suspicious and benign lesions as
well as the identification of melanomas.
New approaches are required to improve GPs’ assess-
ment of pigmented skin lesions. Dermoscopy has been
shown to improve the diagnostic accuracy for melanoma
in the specialist setting [12] and in two randomised con-
trolled trials in general practice [13,14]. However, dermo-
scopy is a relatively time-consuming technique to learn;
in a recent trial of dermoscopy and digital monitoring
Australian GPs required up to 30 hours of internet-based
learning to acquire adequate skills and only 63% of those
trained actually recruited patients into the trial. There is
also current interest in teledermatology but, for suspi-
cious pigmented lesions, it is unlikely to dramatically
reduce the need for conventional clinical consultations
with experts whilst maintaining clinical safety [15].
An innovative approach uses SIAscopy, a non-invasive
multispectral scanning technique which gains micro-
architectural information about the skin within seconds.
The device shines near infrared and visible spectra light
from a handset through the skin. The light remitted can
then be calibrated for papillary dermis thickness, using
information from the infrared wavebands. The amount
of dermal blood is obtained by de-referencing a given
colour location on the surface of normal skin coloura-
tion. If melanin is present in the dermis, its presence
can be detected from the fact that even after the papil-
lary dermis thickness adjustment, the colours still do
not lie on the surface of normal skin colouration. The
amount of epidermal melanin is obtained by de-referen-
cing skin colour locations on the surface of normal skin
colouration. Within seconds all of this information is
displayed graphically on the computer screen as SIAs-
cans. SIAscans are therefore high-resolution images of
the collagen and haemoglobin content of the papillary
dermis, and melanin content of the epidermis and papil-
lary dermis. Patterns within the SIAscans of pigmented
skin lesions (such as the presence of dermal melanin
and blood displacement with erythematous blush)
indicate the pathological changes consistent with mela-
noma. Previous studies have demonstrated the diagnos-
tic accuracy of SIAscopy for melanoma amongst
patients referred to secondary care using the Moncrieff
scoring system [16,17]. In that study the combination of
the following features was found to be sensitive and spe-
cific for the diagnosis of melanoma: presence of dermal
melanin, collagen holes, erythematous blush and blood
displacement (see Figure 1). However, the findings of
diagnostic studies on referred populations cannot be
applied to patients seen in primary care due to the
potential for spectrum bias. The primary aim of this
study therefore was to develop and validate a scoring
system for SIAscopic diagnosis of pigmented skin
lesions encountered in primary care. In addition, since
all studies to date on SIAscopy have been conducted in
the UK, we aimed to validate the technique in an Aus-
tralian primary care setting to examine its generalisabil-
ity to populations with greater sun-related skin damage.
Methods
This study was conducted in two consecutive settings in
the UK and Australia and entailed the following three
stages:
1. Development of the primary care scoring algo-
r i t h m( P C S A )o nas u b - s e to fl e s i o n sf r o mt h eU K
sample (UK Development lesion dataset);
2. Validation of the PCSA on a different sub-set of
lesions from the same UK sample (UK Validation
lesion dataset);
3. Validation of the PCSA on a new set of lesions
from an Australian primary care population (Austra-
lian Validation lesion dataset).
Ethical approval
Ethical approval for the UK component of the study was
obtained from the Cambridge Research Ethics Commit-
tee (REC Ref. 04/079) and research governance approval
from Cambridge City and South Cambridgeshire Primary
Care Trusts (Project number L00569). Ethical approval
for the Australian component of the study was obtained
from the University of Western Australia’sH u m a n
Research Ethics Committee (HREC Ref. RA/4/1/1739).
Settings
UK setting
Six general practices were recruited from Cambridge city
and the surrounding suburban and rural areas covering a
registered population of 52,913. Adult patients aged over
18 years were recruited into the study by their general
practitioner (GP) if they had presented with concerns
about a pigmented skin lesion: as these were lesions
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lesions that were ultimately considered not clinically sus-
picious. Participants were formally consented and data
collected about their lesion by JH within two weeks of
initial presentation to their GP. Data collection occurred
between January 2005 and January 2006.
Australian setting
Three primary care skin cancer clinics operated by GPs
were recruited from the metropolitan area of Perth,
Western Australia. Adult patients aged over 18 years
were recruited into the study by their GP if they pre-
sented with concerns about a pigmented skin lesion:
again, these included lesions that ultimately were con-
sidered not clinically suspicious. Additional lesions were
also included when a pigmented skin lesion was identi-
fied as potentially suspicious during their clinical exami-
nation. Participants were formally consented and data
collected by AJW on the same day as they presented to
their GP. Data collection occurred between April 2008
and January 2009.
Data collection
The following data were collected by the medically qua-
lified researchers (JH or AJW) for each skin lesion:
1. 7-point melanoma checklist
11;
2. Macroscopic digital photograph (Canon EOS 400
D camera, Canon EF-S60 macro lens, Canon
MR-14EX Macro Ring Lite flash, JPEG picture for-
mat: 3888 × 2592 pixels);
3. Dermoscopic digital photograph (Canon EOS 400
D camera, Canon EF-S60 macro lens, Heine SLR
Photadaptor, Heine Delta 20 dermatoscope, JPEG
picture format: 3888 × 2592 pixels);
4. SIAscan (MoleMate™SIAscope V and Microsoft
Windows™application).
Figure 1 Example SIAscans, with labelled features, of a) benign naevus b) malignant melanoma c) seborrhoeic keratosis d)
haemangioma.
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SIAscan images and data (including the location of the
lesion and the age group and sex of the patient)
were assessed by a SIAscopy expert, who was blinded to
the 7-point melanoma checklist results and clinical
photographs. The SIAscopy expert scored the presence
or absence of each specific SIAscopic feature including
those previously associated with melanoma [16]: size of
lesion, age of patient, dermal melanin, collagen holes
and blood displacement with erythematous blush. Addi-
tional features that were also scored were: blood vessels,
white dots on the collagen view, blood lacunes and a
cerebriform melanin pattern (see Figure 1).
Diagnostic reference standards
Given that it would have been ethically unacceptable to
obtain histological diagnosis on every recruited lesion,
we applied the following hierarchical approach to refer-
ence standard diagnosis:
1. Histopathology.
2. In-person clinical review of the lesion by one
expert, including 7-point checklist and digital
dermoscopy.
3. Clinical diagnosis made on the basis of the 7-
point checklist, photographic and dermoscopy
images.
The expert reviewers were blinded to the SIAscan
images. For the reference standard diagnosis we cate-
gorised lesions in two complementary ways relevant to
primary care decision-making: (1) ‘suspicious’ or benign
and (2) melanoma or other pigmented lesion. The defi-
nition of ‘suspicious’ was a lesion that, if seen in general
practice, would warrant referral, excision or short-term
monitoring.
Analysis
This was undertaken in three stages:
(a) Development stage: a 66% sub-sample of lesions
(UK Development lesion dataset) was scored using the
Moncrieff scoring system. In order to account for the
different prevalence of certain pigmented skin lesions
seen in primary care, a Primary Care Scoring Algorithm
(PCSA) was developed.
(b) Validation stage one: the PCSA was validated
against the remaining 33% sub-sample of lesions (UK
Validation lesion dataset).
(c) Validation stage two: the PCSA was validated
against the lesions recruited in Australia (Australian
Validation lesion dataset).
Data were recorded on a Microsoft Access database
and analysed with Microsoft Excel and SPSS version 11.5
for Windows. Sensitivity, specificity, positive and negative
predictive values and their associated 95% confidence
intervals were calculated using standard approaches
including the Wilson method to account for small sample
sizes in some of the cells [18]. Receiver operating charac-
teristic (ROC) curves and associated area-under-the-
curve (AUC) were created using standard functions
within SPSS 11.5 to explore different cut-off scores for
the PCSA. We compared the area under the curve for the
PCSA and the 7-point checklist for all lesions for which
we had obtained histology, using the manual method
described by Hanley and McNeil [19].
Results
In the UK dataset (development and validation lesions)
interpretable images were obtained on 630 lesions from
389 patients. The mean age of participants in the study
was 44.9 years; 68.6% were female. In the Australian
dataset (validation lesions) interpretable images were
obtained on 581 lesions from 469 patients. Fifty two per
cent of the subjects were male, and the mean age of
participants was 50 years. Table 1 shows the types of
lesion represented in the two datasets based on histo-
pathology where known, or expert clinical diagnosis.
(a) Development stage
Table 2 presents the performance of the Moncrieff scor-
ing system for the diagnosis of ‘suspicious’ using the
Development Lesion dataset (n=422). In this subset
there were 24 suspicious lesions and 3 melanomas,
including 1 atypical melanoma with significant regres-
sion. The Moncrieff scoring system did not perform that
well for the diagnosis of ‘suspicious’, predominantly due
to misclassification of seborrhoeic keratoses and hae-
mangiomas. In particular, of the 101 seborrhoeic kera-
toses in the sample, 55 were misclassified as suspicious
due to apparent ‘dermal melanin’ on the SIAscopic
image. Specific SIAscopic features of seborrhoeic kera-
toses were identified as: white dots on the collagen view,
analogous to milia-like cysts seen on dermoscopy [20],
and a cerebriform appearance on the total melanin view.
Haemangiomas were identified by the presence of blood
lacunes on the SIAscan ‘blood’ view.
Because of this potential to misclassify seborrhoeic
keratoses and haemangiomas, we therefore set out to
develop a new diagnostic algorithm to improve
SIAscopy’s ability to distinguish these lesions, which are
more prevalent in primary care than in referred popula-
tions, from melanoma. An additional feature, the pre-
sence of blood vessels, was entered into the Moncrieff
model to examine its role in improving the diagnostic
performance. ROC curves were plotted, using data from
the Development Lesion dataset, to examine the differ-
ent point scores for the presence of blood vessels. The
performance of the Moncrieff score for ‘suspicious’ was
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haemangiomas, based on SIAscopic features, were
excluded from the dataset (Area Under Curve (AUC):
MSS 0.732; MSS after exclusion of seborrhoeic keratoses
and haemangiomas 0.759). For the diagnosis of mela-
noma, performance was improved by scoring 2 points
for the presence of blood vessels and by excluding
lesions classified as seborrhoeic keratoses or haemangio-
mas, based on SIAscopic features (AUC 0.916, see
Figure 2). On this basis a new Primary Care Scoring
Algorithm (PCSA) was developed that aims to identify
lesions with features of seborrhoeic keratoses or hae-
mangiomas first and then apply a scoring system based
on the presence of other features associated with mela-
noma (see Figure 3). In this way, seborrhoeic keratoses
and haemangiomas are no longer misclassified.
(b) UK Validation stage
The new PCSA was tested against the 208 lesions in the
Validation Lesion dataset, which included 6 suspicious
lesions and two histopathologically confirmed melano-
mas. The performance of the PCSA is presented in
Table 2.
(c) Australian Validation stage
The PCSA was tested against the 581 lesions recruited
in Australia. There were 52 suspicious lesions includ-
ing 5 histopathologically confirmed melanomas and 2
lentigo malignas. The performance of the PCSA is pre-
sented in Table 2. In this second validation stage, the
sensitivity for the diagnosis of suspicious was similar
to the UK findings (0.44; 95% CI 0.32-0.58). However,
specificity was significantly better (0.95; 95% CI 0.93-
0.97). Furthermore, due to the higher prevalence of
suspicious lesions in the Australian dataset, the posi-
tive predictive value for the diagnosis of suspicious was
0.52 (95% CI 0.38-0.66) while maintaining an accepta-
bly high negative predictive value (0.95; 95% CI 0.92-
0.96).
We compared the AUC for the PCSA and the 7-point
checklist for the 111 lesions for which we had histologi-
cal diagnosis (n = 42 UK dataset; n = 69 Australian
dataset; included 10 melanomas and 2 lentigo maligna)
(Table 3; Figure 4). The PCSA had a significantly
greater AUC (0.83; 95% CI 0.71-0.95) than the 7-point
checklist (AUC 0.61; 95% CI 0.44-0.78; p = 0.02 for
difference).
Table 2 Performance characteristics of SIAscopy for the diagnosis of ‘suspicious’ in the different datasets of lesions.
Development dataset
(Moncrieff scoring system)
UK validation dataset
(PCSA)
Australian validation dataset (PCSA)
Sensitivity
(95% CI)
0.54 (0.35 - 0.72) 0.50 (0.18-0.81) 0.44 (0.32-0.58)
Specificity
(95% CI)
0.77 (0.73 - 0.81) 0.84 (0.78-0.88) 0.95 (0.93-0.97)
Positive predictive value
(95% CI)
0.12 (0.075 - 0.20) 0.09 (0.03-0.22) 0.52 (0.38-0.66)
Negative predictive value
(95% CI)
0.96 (0.93 - 0.98) 0.98 (0.95-0.99) 0.95 (0.92-0.96)
Table 1 Distribution of lesions in Development and Validation datasets, based on expert clinical diagnosis or
histology where available
Diagnosis Development dataset % UK validation dataset % Australian validation dataset %
Naevus 293 69. 4% 159 76. 4% 333 57. 3%
Seborrhoeic keratosis 101 23. 9% 39 18. 7% 128 22. 0%
Solar lentigo 0 0 0 0 67 11. 5%
Basal cell carcinoma 0 0 0 0 22 3. 8%
Melanoma 3 0.7% 2 1. 0% 7 1. 2%
Angiokeratoma 0 0.0% 0 0.0% 6 1. 0%
Dermatofibroma 14 3. 3% 6 2. 9% 5 0.9%
Lentigo maligna 0 0.0% 0 0.0% 4 0.7%
Haemangioma 11 2. 6% 2 1. 0% 0 0.0%
Lentigo simplex 0 0.0% 0 0.0% 5 0.9%
Ephilis 0 0.0% 0 0.0% 3 0.3%
Papilloma 0 0.0% 0 0.0% 1 0.2%
Total 422 208 581
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SIAscopy as haemangioma or seborrhoeic keratosis. Red = Moncrieff Scoring System 
(MSS); green = MSS +1 point for blood vessels; blue = MSS + 2 points for blood vessels; 
yellow = MSS +3 points for blood vessels.  
Area under curve: Red = 0.892; green = 0.912; blue = 0.916; yellow = 0.887. 
Figure 2 ROC curves to show development of Primary Care Scoring Algorithm; ROC for diagnosis of melanoma after removal of
lesions classified on SIAscopy as haemangioma or seborrhoeic keratosis.
Figure 3 Primary Care Scoring Algorithm (PCSA).
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This is the first study to test the use of SIAscopy for
lesions encountered in a primary care setting and also
outside the UK. We have applied a systematic approach
in which we tested the initial Moncrieff scoring system
to see how it would function on lesions presented in a
primary care setting. This is an important step in studies
of new diagnostic techniques to reduce the effects of
spectrum bias. In addition to developing a new diagnos-
tic algorithm we have conducted a second validation
study on a different primary care population. This sec-
ond validation study was conducted in an Australian
primary care setting which, except for a higher preva-
lence of solar lentigos, had a similar prevalence of
lesions to the UK dataset. We accept that a limitation of
this study is our inability to obtain histopathological
diagnoses on all the lesions recruited, but this would
have been ethically unacceptable. To inform the clinical-
expert reference-standard diagnosis we deliberately
chose to obtain maximum clinical data, including the
7-point checklist and dermoscopy. We chose to do this
so we could be as accurate as possible with our refer-
ence diagnosis where histology was not available. It is
also theoretically possible that some amelanotic melano-
mas were not recruited into the study on the basis of
our inclusion criteria. Furthermore, we did not follow-
up any lesions determined as benign so it is theoretically
possible that some clinically significant lesions may have
been missed by our reference standard diagnoses.
The Moncrieff scoring system was found to be less
accurate than in the secondary care setting due to the
different prevalence of lesions among the primary care
population. In order to account for the higher preva-
lence of non-melanocytic lesions, such as seborrhoeic
keratoses and haemangiomas, we developed a new
Primary Care Scoring Algorithm which was more speci-
fic than the Moncrieff scoring system for ‘suspicious’
but no more sensitive. Higher specificity was particularly
identified in the Australian dataset suggesting that sun-
related skin damage does not adversely affect the diag-
nostic accuracy of SIAscopy. The current algorithm
accounts for size of lesion (> 6 mm) and age of patient.
The mean age of participants from each studied popula-
tion was 45 and 50 years respectively. It is not possible
therefore to comment on the performance of the PCSA
in elderly populations in which the algorithm may
become less specific. It was reassuring that the PCSA’s
moderate sensitivity for ‘suspicious’ does not appear to
be reflected in its sensitivity for melanoma, but inevita-
bly there were too few melanomas in this study to pro-
vide robust estimates of diagnostic accuracy for
melanoma in primary care. In subsequent research,
simulation modelling of the PCSA in which a higher
prevalence of melanomas was entered into the dataset
suggests high sensitivity and specificity to detect mela-
noma [21]. Ultimately, a primary care algorithm should
be good at identifying ‘suspicious’ pigmented lesions,
including melanoma, as well as accurately ruling out
lesions which are unlikely to be clinically significant. It
is interesting that the PCSA appears to be more accu-
rate than the 7-point checklist in diagnosing melanoma.
The 7-point checklist was completed by the two medi-
cally qualified and trained researchers including one
who was a plastic surgeon (JH). The relatively poor per-
formance of the 7-point checklist cannot be explained
by inconsistent application of the items. There were sev-
eral non-melanocytic lesions which were thought clini-
cally to be pigmented. The 7-point checklist, and
Siascopy, are intended for use only with melanocytic
lesions, although in clinical p r i m a r yc a r ep r a c t i c et h i s
distinction can sometimes be difficult. The inclusion of
non-melanocytic lesions may partially explain the poorer
performance of the 7-point checklist compared to pre-
viously published data.
Table 3 Distribution of lesions for which histological
diagnosis was available.
Diagnosis Number %
Naevus 62 55. 9
Seborrhoeic keratosis 16 14. 4
Melanoma* 12 10.8
Basal cell carcinoma 9 8. 1
Solar lentigo 5 4. 5
Dermatofibroma 5 4. 5
Lentigo simplex 2 1. 8
TOTAL 111
*includes 2 lentigo maligna
Figure 4 Comparative ROC curves for the Primary Care Scoring
Algorithm and 7-point checklist for lesions with a histological
diagnosis (n = 111; 10 melanoma and 2 lentigo maligna).
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selection bias in the sampling of lesions chosen for
biopsy. This is theoretically possible, for example if the
7-point score were used to inform the clinical decision
to excise, and so our finding should be interpreted with
some caution[22].
In this study we used experts in SIAscopy to interpret
the SIAscans. This therefore reflects the best perfor-
mance of SIAscopy in primary care and not how it would
perform in the hands of general practitioners. As this is
the first study of SIAscopy on lesions from primary care,
we needed to determine the best possible performance of
the technique in experienced hands. We are now con-
ducting a randomised controlled trial of training English
general practitioners in SIAscopy, including the applica-
tion of the PCSA, to determine its effects on clinical
practice (the MoleMate UK Trial). This trial will provide
further evidence on the diagnostic accuracy of the PCSA
when used by general practitioners as well as the cost-
effectiveness of SIAscopy in English primary care.
We believe that the features of SIAscopy may be a
great deal easier to learn than those of dermoscopy
which can take a long period of training in which to
become proficient. A recent study we have conducted
suggests that SIAscopy features can be learnt by general
practitioners using a CD-rom based tutorial in approxi-
mately two hours [23]. In a recent trial in general prac-
tice, dermoscopy had a sensitivity of 55% and specificity
of 89% for malignant lesions which is comparable with
our findings for SIAscopy, albeit in expert hands [14].
The MoleMate UK Trial will provide more comparable
d a t ai nd u ec o u r s e[ 2 4 ] .W h i l et h e r ei sn od o u b tt h a t
dermoscopy and digital monitoring can significantly
improve the management of pigmented lesions in pri-
mary care, we believe that SIAscopy could be simpler to
learn and may therefore have greater utility for a wider
group of primary care practitioners than dermoscopy.
Conclusions
The PCSA for SIAscopy could have an important role in
improving the management of pigmented skin lesions in
primary care. This study has confirmed the key diagnos-
tic features of lesions commonly encountered in primary
care. Further work is required to determine the impact
of training GPs in SIAscopy on their clinical manage-
ment of pigmented skin lesions, and the quality of their
referrals to the secondary care skin cancer clinics.
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